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Abstract
Background: The most dominant feature in chronic pancreatitis is intense abdominal pain. Changes in spinal and/or
supraspinal central nervous system pain processing due to visceral nociceptive input play an important role in this pain.
How altered pain processing is related to disease stage still needs study.
Methodology/Principal Findings: Sixty chronic pancreatitis patients were compared to 15 healthy controls. Two subgroups
of pancreatitis patients were defined based on the M-ANNHEIM severity index of chronic pancreatitis; i.e. moderate and
severe. Pain detection and tolerance thresholds for pressure and electric stimuli were measured in six selected dermatomes
(C5, T4, T10, L1, L4 and T10BACK). In addition, the conditioned pain modulation response to cold pressor task was
determined. These measures were compared between the healthy controls and chronic pancreatitis patients. Severe
pancreatitis patients showed lower pain thresholds than moderate pancreatitis patients or healthy volunteers. Healthy
controls showed a significantly larger conditioned pain modulation response compared to all chronic pancreatitis patients
taken together.
Conclusions/Significance: The present study confirms that chronic pancreatitis patients show signs of altered central
processing of nociception compared to healthy controls. The study further suggests that these changes, i.e. central
sensitization, may be influenced by disease stage. These findings underline the need to take altered central pain processing
into account when managing the pain of chronic pancreatitis.
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Introduction
Intense upper abdominal pain is common in chronic pancre-
atitis patients and is the most important predictor of health-related
quality of life. [1,2] The etiology of pain remains to be elucidated
and no generally accepted guidelines exist for its treatment. Initial
treatment typically consists of a low fat diet and non-narcotic
analgesics. [2] Alternatives to medical treatment, e.g. pancreatic
surgery, thoracoscopic splanchnicectomy and lithotripsy, may
have an effect on pain in selected patients. [3–5] If no acceptable
pain relief is obtained, opioids remain the mainstay for the
management of pain. However, opioids have many adverse effects
such as negative influence on gastrointestinal motility, central
nervous system toxicity, addiction and abuse potential, and
sometimes opioid induced hyperalgesia. [6] Thus new treatment
regimes for the debilitating pain of chronic pancreatitis are still
needed. Adjuvant therapy with, e.g., pregabalin has recently been
proven to be effective in chronic pancreatitis. [7,8] However,
centrally acting agents i.e. gabapentinoids or tricyclic antidepres-
sants are not yet an accepted part of pain treatment in chronic
pancreatitis.
Answering questions like ‘‘How do chronic pancreatitis patients
process pain and how does altered pain processing relate to their
pain experience?’’ is fundamental for the design of new therapeutic
strategies. In human experimental pain models basic pain
mechanisms can be explored by quantitative sensory testing
(QST), electroencephalography or MRI. [9–12] These techniques
provide insight into various aspects of pain processing during
progression of a painful disease, as well as before and after a
therapeutic intervention [13].
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QST is increasingly used to study pain mechanisms in painful
conditions. [13–16] A key described alteration in chronic
pancreatitis patients is segmental and generalised hyperalgesia,
often present despite (or because of) opioid usage. [9,17] These
changes are similar to those seen in neuropathic pain syndromes.
[11] Their presence suggests that increased sensitivity in the
central nervous system at spinal and/or supraspinal sites (‘‘central
sensitization’’) plays an important role in chronic pancreatitis pain,
and that this is not effectively modulated by current opioid based
therapies. [11] Conditioned pain modulation (CPM) is a dynamic
QST paradigm designed to activate and measure pain modulating
mechanisms, e.g. via descending inhibitory control where brain
stem centers act on nociceptive neurons in the dorsal horn of the
spinal cord. [18] An impaired CPM response has been reported in
chronic pancreatitis as well as in other gastrointestinal diseases and
neuropathic conditions exhibiting hyperalgesia [19–21].
At present, comprehensive comparisons between chronic
pancreatitis patients at different disease stages and compared with
a healthy population regarding pain processing are not available.
Such observations related to disease progression may also be of
clinical value for other chronic painful disorders e.g. ulcerative
colitis and Crohn’s disease [22].
The objective of this study is to investigate the difference in pain
sensitivity and modulation between healthy subjects and chronic
pancreatitis patients using QST to determine 1) pressure pain
thresholds, 2) electric pain thresholds and 3) CPM response. Our
hypothesis is that pain in chronic pancreatitis is accompanied by
alterations in pain processing, and that this is influenced by disease
stage [23].
Methods
Study Patients
The study was approved by the responsible Ethical Committees
in both countries (CMO region Arnhem-Nijmegen, Nijmegen,
The Netherlands and The local Ethics Committee North Region,
Aalborg, Denmark) and all patients provided written informed
consent. Patients were recruited for an investigator initiated
double-blind, placebo-controlled, parallel-group study of increas-
ing doses of pregabalin conducted in the Netherlands (department
of Surgery, Radboud University Nijmegen Medical Center) and
Denmark (department of Gastroenterology, Aalborg Hospital,
Aarhus University Hospital. The study was powered on a clinical
primary outcome measure which is presented in another
Figure 1. Study enrollment and randomization. The majority of patients ‘not meeting inclusion criteria’ had either died, was pain free or was no
longer being treated in either of the hospitals.
doi:10.1371/journal.pone.0055460.g001
Table 1. M-ANNHEIM severity index of chronic pancreatitis
and distribution of patients.
Severity level Point range Frequency no. (%)
M-ANNHEIM A Minor 0–5 4 (7)
M-ANNHEIM B Increased 6–10 30 (50)
M-ANNHEIM C Advanced 11–15 21 (35)
M-ANNHEIM D Marked 16–20 4 (7)
M-ANNHEIM E Exacerbated .20 1 (2)
M-ANNHEIM scoring system points are added together, and the sum is used to
categorize a patient’s disease according to the M-ANNHEIM severity index.
doi:10.1371/journal.pone.0055460.t001
Pain Processing and Disease Stage in Pancreatitis
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manuscript [7] and not on the QST measurements that are
described in this manuscript. The present study only presents the
baseline QST results of all the 64 patients that were included in
this trial.
To be included in this study, patients needed to have chronic
abdominal pain typical for pancreatitis (i.e. dull epigastric pain
more than 3 days per week for at least 3 months) and a diagnosis of
chronic pancreatitis based on The Mayo Clinic diagnostic criteria.
[24] Patients were excluded from the study if they had a painful
condition other than chronic pancreatitis, an active (or history of)
major depression, severe renal impairment, an abnormal electro-
cardiogram at screening, allergy to pregabalin or any of it
components and were pregnant or lactating.
Healthy Controls
A healthy control group was recruited in Denmark for
comparison with our chronic pancreatitis group. The controls
did not have any active disease and no history of a medical
condition that could interfere with our pain measurements.
Measurements were performed in females in the same phase of
the menstrual cycle. Informed consent was provided by all healthy
controls.
Quantitative Sensory Testing
QST took place using a standard temporal test sequence. [9]
Testing in females with pancreatitis was not standardized with
regard to phase of the menstrual cycle because all pancreatitis
patients had amenorrhea or were postmenopausal. After initial
QST training, pressure pain thresholds were obtained for muscles
overlying bone using a pressure algometer with a 1.0-cm2 probe
(Somedic Sales AB, Horby, Sweden), at each of the following sites
on the dominant body side: lower neck (C5 dermatome), sternum
(T4 dermatome), pancreatic site (dorsal (T10 dermatome) and
ventral (T10BACK dermatome)), hip region (L1 dermatome) and
knee (L4 dermatome).
The pancreatic and more distant dermatomes were chosen to
permit observation of segmental and spreading hyperalgesia
respectively. The upper abdominal area (T10 ventral and dorsal)
was chosen to detect segmental hyperalgesia because dorsal horn
neurons receiving painful stimuli from this skin area also receive
nociceptive stimuli from the pancreas (i.e. pancreatic area). To
examine spreading and generalized hyperalgesia we chose 2
dermatomes (proximal and dorsal) near the pancreatic area
(dermatomes T4 and L1) and 2 dermatomes more distant
(proximal and dorsal) from the pancreatic area (dermatomes C5
and L4). The more distant areas were chosen to act as a control
Table 2. Demographic and clinical characteristics of patients and healthy controls.
Healthy controls (n=15)
Moderate chronic
pancreatitis group (n =34)
Severe chronic pancreatitis
group (n=26)
Age (years) 4069* 53611 53611
Males - no. (%) 8 (53) 24 (71) 12 (46)
Etiology - no. (%)
- Toxic-metabolic 0 17 (50) 13 (50)
- Idiopathic 0 13 (38) 8 (31)
- Genetic 0 1 (3) 1 4)
- Autoimmune 0 0 1 (4)
- Recurrent and severe acute pancreatitis 0 2 (6) 1 (4)
- Obstructive 0 1 (3) 2 (8)
Diary pain score (numeric rating score 0–10)
- Average pain 0 462 462
- Maximal pain 0 562 662
Concomitant analgesics - no. (%){
- None 0 4 (12) 1 (4)
- Weak analgesics 0 7 (21) 10 (39)
- Strong analgesics 0 23 (68) 15 (58)
MEQ/day 0 1126132 72671
Antidepressants - no. (%) 0 6 (18) 6 (23)
Duration of chronic pancreatitis (months) 0 113685 100675
Diabetes mellitus - no. (%) 0 4 (12) 14 (54)*
Previous interventions for chronic pancreatitis – no. (%) 0 2 (6) 13 (50)*
- Pancreas resection/drainage procedures 0 2 (6) 8 (31)*
- Thoracoscopic splanchnic denervation 0 1 (3) 7 (27)*
- Coeliacus blocade 0 0 2 (8)*
Patients treated with enzymes for pancreatic exocrine
insufficiency - no. (%)
0 11 (32) 17 (65)
All values are means with standard deviations unless mentioned otherwise. Percentages may not total 100 due to rounding. {Weak analgesics were defined as NSAIDS,
paracetamol, codeine and tramadol. Strong analgesics were defined as opioid based therapies. ‘MEQ’ is morphine equivalents. Values marked with an asterisk were
significantly different from each other.
doi:10.1371/journal.pone.0055460.t002
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area likely unaffected by pancreatic nociceptive input because the
nociceptive pathways from these areas are well-separated from
those coming from the pancreas at both peripheral and spinal
levels.
Two thresholds were measured: pressure pain detection
threshold (pPDT) and pressure pain tolerance threshold (pPTT).
Thresholds to electric constant current skin stimulation
(Digistim; Biometer A/S, Copenhagen, Denmark; tetanic stimu-
lation at 100 Hz, 0.2-ms square waves, self-adhesive electrodes
3 cm apart) were measured on the same sites as for pressure
stimulation. Two thresholds were measured: electric pain detec-
tion threshold (ePDT) and electric pain tolerance threshold
(ePTT).
The conditioned pain modulation (CPM, previously known as
DNIC) paradigm was carried out to test the ability of the patient to
generate descending inhibitory modulation. [25,26] Thus pressure
pain tolerance thresholds (pPTT, the test stimulus) were deter-
mined before and after the cold pressor task (the conditioning
stimulus), and the CPM effect was determined as the relative
change (%) in pPTT. For the cold pressor task the dominant hand
was immersed in ice-chilled water (1.0uC60.3uC) continuously
stirred by a pump. The patient was told to remove the hand from
the water after 2 minutes of immersion - or sooner if the pain was
considered to be intolerable – and the immersion time noted.
Immediately after the cold pressor task, the subjects rated the pain
experienced during the test by use of a visual analogue scale for
quality control purposes. pPTT were obtained in the non-
dominant L4 dermatome (knee) immediately before and after
ice-water immersion.
Disease Stage
We formed two groups of patients based on ‘the M-ANNHEIM
severity index of chronic pancreatitis’ which is a validated clinical
disease stage classification for chronic pancreatitis. [27] The M-
ANNHEIM classification system incorporates etiology, different
stages of the disease, and various degrees of clinical severity. The
M-ANNHEIM scoring system for a clinical severity index is a
simple, accurate and noninvasive tool in clinical practice and may
be helpful in investigating the impact and interaction of various
risk factors on the course of the disease. Clinical severity is based
on pain control, surgical interventions, pancreatic endocrine and
exocrine insufficiency, morphological status and severe organ
complications.
We divided the patients in two groups based on their score,
namely: #10 points, moderate chronic pancreatitis group
(including: minor and increased severity level) and .10 points,
severe chronic pancreatitis group (including: advanced and
marked severity level).
Statistical Analysis
The study was powered to detect a difference in average daily
pain scores of 25% between groups during the 3 weeks of study
treatment. We determined that a study with 30 patients per group
was needed to provide a power of 90% with the use of a 2-sided
significance level of 0.05. Hence, the sample size was set at 64
patients to allow for possible dropouts.
We performed statistical analysis using the Statistica for
Windows Software Package (Release 6.0, Statsoft Inc., Tulsa,
OK, USA). All results are given as means with standard deviations
or 95% confidence intervals as appropriate. We analyzed QST
Figure 2. Pressure pain detection thresholds. The horizontal axis shows all six dermatomes, the vertical axis shows pressure pain detection
thresholds (pPDT) in kPa. The difference between study groups and all six dermatomes for pPDT is significant (F = 3.75, p,0.0001). Results are means
with 95% CI. ‘control’ is healthy control group, ‘moderate’ is moderate chronic pancreatitis group and ‘severe’ is severe chronic pancreatitis group.
doi:10.1371/journal.pone.0055460.g002
Pain Processing and Disease Stage in Pancreatitis
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results using a mixed model two-way ANOVA with one between
subjects factor (GROUP; i.e. a healthy control group and two
chronic pancreatitis groups according to disease stage) and one
within subjects factor (SITE; consisting of the six dermatomes
mentioned under quantitative sensory testing). We analyzed CPM
results using a one-way ANOVA with one between subjects factors
(GROUP; as above). Post hoc analysis was performed using
Fisher’s least significant difference test.
Results
Study Population
From October 2008 to May 2010 a total of 236 patients
diagnosed with chronic pancreatitis in the last five years in one of
both hospitals were screened and 64 patients were randomized;
the study was completed without any incident. The majority of
patients not meeting inclusion criteria were pain free, had passed
away or were no longer being treated in either of the hospitals.
From those 64 patients, four patients were excluded due to a new
pain condition (e.g. complication of chronic pancreatitis requiring
surgery, tooth-abscess, emergency vascular surgery and diagnosis
of IBD) that would interfere with their QST measurements
(Figure 1). All patients in this per protocol analysis (24 women, 36
men; mean age 54611) had pain due to chronic pancreatitis and
were on a stable analgesic therapy. The healthy control group
consisted of 15 volunteers. The moderate chronic pancreatitis
group consisted of 34 patients and the severe group of 26 patients
(Table 1). Pancreatitis groups were statistically comparable except
– as expected – for previous interventions. More demographic
data on the study population and control group are listed in
Table 2.
Thresholds to Pressure Stimulation
For pPDT, there were significant differences between groups
overall (GROUP; F= 8.88, p,0.001). Post-hoc analysis showed
overall significantly lower thresholds for the severe chronic
pancreatitis group compared to healthy controls (p = 0.001) and
moderate pancreatitis group (p =,0.001). As expected, thresholds
were significantly different according to dermatome of measure-
ment (SITE; F= 45.28, p,0.0001). A significant interaction was
found for SITE and GROUP (F=3.75, p,0.0001) (Figure 2).
Post-hoc analysis showed significantly lower thresholds for
dermatome L1 (p = 0.04), L4 (p= 0.04) and T10BACK
(p= 0.05) in the severe chronic pancreatitis group compared to
the moderate chronic pancreatitis group.
For pPTT there were no significant thresholds differences
between groups overall, but only a trend (GROUP; F=2.99,
p = 0.06). Thresholds in the different dermatomes again signifi-
cantly differed (SITE; F= 80.72, p,0.0001). A significant
interaction between SITE and GROUP (F= 3.27 and
p=,0.001) was seen (Figure 3). However post hoc analysis was
not significant, with only a trend to lower thresholds between the
severe pancreatitis group and healthy controls for the pancreatic
dermatome (p = 0.07).
Thresholds to Electrical Stimulation
ePDT thresholds differed significantly according to dermatome
(SITE; F= 17.48, p,0.0001) and groups overall (GROUP;
F= 4.34, p = 0.02). Post hoc analysis for GROUP showed overall
significantly lower thresholds for the severe chronic pancreatitis
group compared to healthy controls (p = 0.007) and for the severe
chronic pancreatitis group compared to the moderate chronic
pancreatitis group (p = 0.03). There was also a significant
interaction between SITE and GROUP (F= 3.72, p,0.0001)
Figure 3. Pressure pain tolerance thresholds. The horizontal axis shows all six dermatomes, the vertical axis shows pressure pain tolerance
thresholds (pPTT) mentioned in kPa. The difference between study groups and all six dermatomes for pPTT is significant (F = 3.27, p,0.001).
doi:10.1371/journal.pone.0055460.g003
Pain Processing and Disease Stage in Pancreatitis
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(Figure 4). Post hoc analysis was not significant, with only a trend
to lower thresholds for the severe pancreatitis patients in L1
compared to healthy controls (p = 0.053), but without obvious
difference between other dermatomes.
For ePTT thresholds differed significantly for GROUP (F= 3.9,
p = 0.03), with again a significant post-hoc analysis for overall
lower thresholds for the severe chronic pancreatitis group
compared to healthy controls (p = 0.02) and for the severe chronic
pancreatitis group compared to the moderate chronic pancreatitis
group (p = 0.02). Thresholds differed significantly for SITE
(F= 12.98, p,0.0001). The interaction between SITE and
GROUP was not significant (F = 0.91, p= 0.53) (Figure 5).
Conditioned Pain Modulation
The baseline pressure pain tolerance thresholds for dermatome
L4 were not significantly different between groups (pPTT L4:
F= 0.8; p = 0.45). Chronic pancreatitis patients and healthy
controls showed an increase in thresholds after the cold pressor
task. The moderate chronic pancreatitis patients tolerated the cold
pressor task for 66659 sec and the severe chronic pancreatitis
patients for 36627 sec vs. healthy controls with 18061 sec –
which was significantly different overall (F = 52.2 and p,0.0001).
Post hoc analysis was only significant for the healthy controls vs.
the two pancreatitis groups (p,0.0001).
The effect of CPM was smaller in the patient groups compared
to the controls, but the difference between groups was not
significant (GROUP; F= 2.2; p = 0.13; controls: mean
32.8%68.9% vs. moderate: 13.5%621.4% vs. severe:
10.3%639.9%). When all pancreatitis patients were taken
together and compared to healthy controls, there was a significant
difference (p = 0.04; controls: mean 32.8%68.9% vs. pancreatitis:
12.0%64.8%).
Discussion
Our study confirms that patients with chronic pancreatitis show
signs of central sensitization, manifest as lower pain thresholds
compared to healthy controls. Our results suggest that patients
with more severe disease exhibit more central sensitization. We
were unable to demonstrate a relation between disease stage and
effectiveness of inhibitory pain modulation.
Altered Pain Processing
Peripheral nociception at the site of the pancreas spreads via
ascending pathways of the spinal cord to supraspinal structures
including the cortex. [28,29] If neurons at the spinal cord undergo
neuroplastic changes, these changes will typically manifest as
segmental hyperalgesia in the corresponding segments. [11,30]
Increased nociceptive drive on secondary neurons leading to
hyperexcitability and firing of supraspinal neurons at lower
thresholds can then be expected to ultimately result in spreading
and generalized hyperalgesia. [11] Our findings are compatible
with the above described changes and EEG studies in chronic
pancreatitis pain patients showing alterations in the organization
of the pain matrix. [12,31] The main interest of our study is its
provision of first evidence that patterns of altered pain processing
may also reflect disease stage and progression.
The effect of endogenous feedback systems on nociceptive input
can be measured using the conditioned pain modulation (CPM)
paradigm, which reflects effects of descending control from the
brain on second-order neurons in the spinal cord. [32] Recent
Figure 4. Electric pain detection thresholds. The horizontal axis shows all six dermatomes, the vertical axis shows electric pain detection
thresholds (ePDT) in mA. The difference between study groups and all six dermatomes for ePDT is significant (F = 3.72, p,0.0001).
doi:10.1371/journal.pone.0055460.g004
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evidence suggests that patients with chronic painful diseases like
chronic pancreatitis may exhibit less effective descending inhibi-
tory control. [21,33] Our study confirms this result.
Both peripheral and central pain signaling are potentially
sensitized in chronic pancreatitis. Several studies provide evidence
for peripheral visceral nerve damage in chronic pancreatitis. [11]
The presence of central sensitization demonstrated in chronic
pancreatitis patients in the present study (and others) means that
pain signaling is exaggerated in the central nervous system too.
This central sensitization can be due to either a direct increase of
sensitivity of neural structures, or due to a loss of inhibitory
modulation of neural structures. The latter is tested by the CPM
paradigm and was unaffected by disease stage but greater in
chronic pancreatitis patients vs. healthy controls. The lacking
effect of disease stage on CPM could be real or due to lacking
study power in the face of greater variability in CPM measures as
compared to pain thresholds. [34] Clearly this topic needs further
investigation in a larger patient collective.
Clinical Implications
The findings concerning variations in supraspinal central
sensitization in relation to disease stage suggest implications
regarding treatment approaches in chronic pancreatitis. Firstly, it
has been demonstrated that degree of hyperalgesia in neuropathic
pain patients is inversely related to analgesic efficacy of opioids.
[35] If this applies in chronic pancreatitis, then increasing
hyperalgesia will be linked to decreasing analgesic efficacy of
opioids – and probably also increased risk of opioid-induced
hyperalgesia. [36] Secondly, therapeutic measures aimed at
nociceptive deafferentation alone (e.g. splanchnic denervation,
surgery aimed at specific anatomical causes, peripheral analgesia)
are unlikely to be effective unless combined with specific
treatments targeting central sensitization (e.g. gabapentinoids,
tricyclic antidepressants and ketamine). [2,7,11,37,38] This is
again more likely to be the case in patients with more hyperalgesia,
which in turn appears related to disease stage. Finally, there are
indications that long-term, ongoing nociceptive input may result in
supraspinal alterations to pain processing becoming independent
of peripheral nociceptive input (autonomy). [6] This likely renders
therapeutic measures aimed at depressing peripheral nociceptive
input ineffective, making treatment of altered central pain
processing the foundation of pain treatment in these patients.
[2,11] Such a course of events leading to autonomy would appear
more likely in patients with more hyperalgesia and a longer history
of their disease – and may again be related to disease stage. The
diagnostic and therapeutic implications of these observations
deserve further study.
Other Chronic Pain Disorders
Our results support the hypothesis that patients with more
severe disease exhibit more central sensitization. This hypothesis is
further supported by other studies regarding relationships between
disease severity, degree of central sensitization and therapeutic
effect. For CRPS, a clear relationship between degree of central
sensitization and disease progression has been demonstrated. [39]
In inflammatory bowel disease and endometriosis a relation has
been found between segmental or generalized hyperalgesia as a
sign of central sensitization and clinical difficulty in controlling
pain. [16,22,40] Similar results have been described in the past in
Crohn’s disease and ulcerative colitis, where the degree of central
sensitization was related to extent of bowel inflammation. [41–44]
Clearly more research is needed in chronic pain patients to
Figure 5. Electric pain tolerance thresholds. The horizontal axis shows all six dermatomes, the vertical axis shows electric pain tolerance
thresholds (ePTT) in kPa. The difference between study groups and all six dermatomes for ePTT is non-significant (F = 0.91, p = 0.53).
doi:10.1371/journal.pone.0055460.g005
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establish the relation between disease severity, changes in the
central nervous system processing and therapeutic success. As a
result of this, recently we started a longitudinal observational study
with serial QSTs in chronic pancreatitis patients who are early in
their disease to describe changes in pain processing during disease
progression.
Methodological Considerations
A limitation of this study is the relatively small size of the two
chronic pancreatitis disease stage subgroups. Nevertheless, even
the present explorative study provides evidence of significant
differences between healthy controls and a validated classification
of pancreatitis disease stages. A better-powered study might have
provided more robust and significant evidence across all the
modalities and individual dermatomes we measured in our study.
Sensitization of neurons and the extent of sensitization could be
different between different tissues (skin vs. deeper tissues) and
dermatomes. This might explain the differences between electric
pain thresholds (a more superficial stimulus) and pressure pain
thresholds (a stimulus of deeper tissues) in different dermatomes.
The healthy control group is slightly younger than the
pancreatitis group. However, the impact of aging on pain
processing remains controversial, some studies described an
increase of pain thresholds during aging [45], others showed no
effect [46] and some showed a decrease in thresholds during aging
[47].
A further important limitation of this study is that it is only
cross-sectional. For definitive answers, a larger and longitudinal
study will need to be performed. In this study only QST
measurements were performed. Combining QST with EEG
measurements or brain imaging would provide more detailed
data on changes in the central nervous system in relation to pain
processing on which to base more effective therapeutic strategies in
the future. The M-ANNHEIM classification is at the moment the
most comprehensive classification system for different stages of
chronic pancreatitis and various degrees of clinical severity. In our
study the classification proved simple, objective and accurate to
apply [27].
Conclusion and Summary
The present study confirms that chronic pancreatitis patients
show signs of altered central processing of nociception compared
to healthy controls. The study further suggests that these changes
may be influenced by disease stage. These findings underline the
need to take altered central pain processing into account when
managing the pain of chronic pancreatitis and may have
important implications for its treatment. More research is needed
to further characterize the link between disease severity and
progression and its relationship to altered pain processing and
treatment in chronic pancreatitis and other chronic pain disorders.
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